High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease - PubMed (original) (raw)
High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease
I Elovaara et al. J Exp Med. 1993.
Abstract
The frequencies of human T cell lymphotropic virus type 1 (HTLV-1)-specific CD8+ precursor cytotoxic T lymphocytes (pCTL) were quantitated from lymphocytes obtained from the peripheral blood and cerebrospinal fluid (CSF) of infected individuals with and without HTLV-1-associated neurological disease. An estimate of the pCTL was obtained by separating CD8+ cells, plating these cells in limiting dilution, and testing wells for HTLV-1 specific lysis. Targets consisted of autologous lymphoblastoid cell lines (LCL) infected with vaccinia constructs expressing HTLV-1 gene products or LCL pulsed with HTLV-1 synthetic peptides. In patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), the frequency of HTLV-1 p40X-specific pCTL was at least 40-280-fold higher than in asymptomatic HTLV-1-infected individuals. All HAM/TSP patients (five of five) predominantly recognized HTLV-1 products encoded within the pX region. Lower pCTL to env were demonstrated in three patients, and only one of five HAM/TSP patients had pCTL to gag. A synthetic peptide corresponding to the tax region of HTLV-1 (peptide 11-19, amino acid sequence LLFGYPVYV) was recognized in association with human histocompatibility leukocyte antigen (HLA)-A2 in two HLA-A2 HAM/TSP patients with a high CD8+ pCTL frequency of 1/325 and 1/265, respectively. A second immunodominant region of HTLV-1 tax (peptide 90-55, amino acid sequence VPYKRIEEL) was identified to be restricted by HLA-B14 in two HLA-B14 HAM/TSP patients with a CD8+ pCTL frequency of 1/640 and 1/1,125, respectively. Lymphocytes from the CSF of a patient with HAM/TSP also showed a pCTL frequency against p40X of similar magnitude to that demonstrated from peripheral blood lymphocytes (PBL). The HLA-A2-mediated CSF pCTL activity to the immunodominant tax-specific peptide 11-19 was also comparable to pCTL from PBL. These results indicate that an extremely high pCTL frequency to HTLV-1 tax-encoded peptides may be related to pathogenesis of myeloneuropathy associated with HTLV-1.
Similar articles
- Limited T cell receptor usage by HTLV-I tax-specific, HLA class I restricted cytotoxic T lymphocytes from patients with HTLV-I associated neurological disease.
Elovaara I, Utz U, Smith S, Jacobson S. Elovaara I, et al. J Neuroimmunol. 1995 Dec;63(1):47-53. doi: 10.1016/0165-5728(95)00129-8. J Neuroimmunol. 1995. PMID: 8557824 - HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network.
Goncalves DU, Proietti FA, Barbosa-Stancioli EF, Martins ML, Ribas JG, Martins-Filho OA, Teixeira-Carvalho A, Peruhype-Magalhães V, Carneiro-Proietti AB. Goncalves DU, et al. Inflamm Allergy Drug Targets. 2008 Jun;7(2):98-107. doi: 10.2174/187152808785107642. Inflamm Allergy Drug Targets. 2008. PMID: 18691139 Review. - Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection.
Gessain A. Gessain A. J Neurovirol. 1996 Oct;2(5):299-306. doi: 10.3109/13550289609146894. J Neurovirol. 1996. PMID: 8912206 Review.
Cited by
- Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
Hasegawa A, Murata M, Fujikawa T, Katagiri K, Nagano Y, Masuda T, Kuramitsu M, Nakajima S, Fujisawa JI, Okuma K, Grover P, Kidiga M, Akari H, Kannagi M. Hasegawa A, et al. PLoS Pathog. 2023 Feb 2;19(2):e1011104. doi: 10.1371/journal.ppat.1011104. eCollection 2023 Feb. PLoS Pathog. 2023. PMID: 36730466 Free PMC article. - AIM™ platform: A new immunotherapy approach for viral diseases.
Langan D, Wang R, Tidwell K, Mitiku S, Farrell A, Johnson C, Parks A, Suarez L, Jain S, Kim S, Jones K, Oelke M, Zeldis J. Langan D, et al. Front Med (Lausanne). 2022 Dec 23;9:1070529. doi: 10.3389/fmed.2022.1070529. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619639 Free PMC article. - The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine.
Tu JJ, Maksimova V, Ratner L, Panfil AR. Tu JJ, et al. Front Microbiol. 2022 May 4;13:897346. doi: 10.3389/fmicb.2022.897346. eCollection 2022. Front Microbiol. 2022. PMID: 35602078 Free PMC article. Review. - Extracellular vesicles from HTLV-1 infected cells modulate target cells and viral spread.
Pinto DO, Al Sharif S, Mensah G, Cowen M, Khatkar P, Erickson J, Branscome H, Lattanze T, DeMarino C, Alem F, Magni R, Zhou W, Alais S, Dutartre H, El-Hage N, Mahieux R, Liotta LA, Kashanchi F. Pinto DO, et al. Retrovirology. 2021 Feb 23;18(1):6. doi: 10.1186/s12977-021-00550-8. Retrovirology. 2021. PMID: 33622348 Free PMC article. - Immunopathogenesis and Cellular Interactions in Human T-Cell Leukemia Virus Type 1 Associated Myelopathy/Tropical Spastic Paraparesis.
Aghajanian S, Teymoori-Rad M, Molaverdi G, Mozhgani SH. Aghajanian S, et al. Front Microbiol. 2020 Dec 22;11:614940. doi: 10.3389/fmicb.2020.614940. eCollection 2020. Front Microbiol. 2020. PMID: 33414779 Free PMC article. Review.
References
- Proc Natl Acad Sci U S A. 1984 Jul;81(14):4544-8 - PubMed
- Virology. 1992 Jun;188(2):628-36 - PubMed
- Ann Neurol. 1987 Feb;21(2):117-22 - PubMed
- Nature. 1987 Jul 23-29;328(6128):348-51 - PubMed
- Nature. 1988 Feb 11;331(6156):540-3 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous